SCHEMBL3207840

SCHEMBL3207840

CC(C)OCCNS(=O)(=O)NC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
CA12 O43570 3/20 0.37
CA14 Q9ULX7 3/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
TSHR P16473 2/20 0.35
EPHX2 P34913 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP3A4 P08684 1/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3218741 0.90 ALDH1A1 (0.45) ALDH1A1TSHRL3MBTL1CYP3A4RAB9A
SCHEMBL3219197 0.79 CA12 (0.44) ALDH1A1CA12CA14CA7CA9
SCHEMBL3196977 0.76 CA12 (0.37) ALDH1A1CA12CA14CA7CA9
SCHEMBL3204936 0.76 CA12 (0.40) ALDH1A1CA12CA14CA7CA9
SCHEMBL15207559 0.76 CA12 (0.35) CA12CA14TSHR
SCHEMBL16448768 0.75 ALDH1A1 (0.38) ALDH1A1TSHREPHX2L3MBTL1CYP3A4
SCHEMBL22854030 0.74 MEN1 (0.36) ALDH1A1CA12CA14CA7CA9
SCHEMBL3204486 0.73 MAPK1 (0.47) ALDH1A1CA12CA14CA7CA9
SCHEMBL5907932 0.72 ALDH1A1 (0.38) ALDH1A1TSHREPHX2L3MBTL1POLB
SCHEMBL3555994 0.72 EPHX2 (0.47) ALDH1A1TSHREPHX2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US claimed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US claimed
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 ALDH1A1 421/4885CA12 1162/4885CA14 913/4885
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 212/4885CA12 3251/4885CA14 2880/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 118/4885CA12 3135/4885CA14 3444/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 212/4885CA12 3251/4885CA14 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.